Verastem prices $250 million financing alongside cancer-drug data and CEO transition
+1 new source since this summary was written
Verastem Oncology reported early clinical results for its investigational KRAS G12D inhibitor VS-7375 and priced an offering of 30,937,500 shares at $8.00 each plus pre-funded warrants for 312,503 shares at $7.9999 each. In the Phase 1/2 TARGET-D 101 study, VS-7375 produced objective response rates of 41% in pancreatic cancer, 43% in non-small cell lung cancer and 33% in colorectal cancer. Verastem said the financing should generate approximately $250 million in gross proceeds and is expected to close on October 15, 2026, subject to customary conditions. Michael P. Bailey is scheduled to become president and CEO on January 1, 2027, succeeding Daniel Paterson.
Why it matters
If completed, the financing would provide Verastem with capital for VS-7375 development, working capital and general corporate purposes, while increasing the share count and potentially diluting existing holders. The reported response data support the company's plan to begin a Phase 3 pancreatic-cancer study by the end of 2026, but the candidate remains in clinical development.
Key facts
- 1In pancreatic ductal adenocarcinoma, VS-7375 at 900 mg once daily generated an objective response rate of 41% among 22 patients in the second-line-or-later setting. rttnews.com
- 2In non-small cell lung cancer, the 600 mg once-daily dose produced a confirmed objective response rate of 43% among 23 second-line-or-later patients. rttnews.com
- 3In colorectal cancer, VS-7375 used with an anti-EGFR therapy produced an objective response rate of 33% among six patients. rttnews.com
- 4The offering comprises 30,937,500 common shares priced at $8.00 per share and pre-funded warrants for 312,503 shares priced at $7.9999 each. rttnews.com
- 5Verastem expects the offering to close on October 15, 2026, and plans to use the proceeds for VS-7375 development, working capital and general corporate purposes. rttnews.com
- 6Michael P. Bailey is set to become president and CEO on January 1, 2027, while Daniel Paterson will continue as an advisor and board member. rttnews.com
Open questions
- Material 11 describes the financing as a $234.7M transaction, while material 8 reports approximately $250 million in gross proceeds; the materials do not clearly establish whether these figures use different bases.
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.